Acasti Pharma, Inc. - (ACST): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACST POWR Grades
- Sentiment is the dimension where ACST ranks best; there it ranks ahead of 71.83% of US stocks.
- The strongest trend for ACST is in Growth, which has been heading down over the past 173 days.
- ACST ranks lowest in Momentum; there it ranks in the 5th percentile.
ACST Stock Summary
- With a price/sales ratio of 465.99, Acasti Pharma Inc has a higher such ratio than 99.12% of stocks in our set.
- With a year-over-year growth in debt of -79.05%, Acasti Pharma Inc's debt growth rate surpasses only 3.24% of about US stocks.
- The volatility of Acasti Pharma Inc's share price is greater than that of 95.44% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to ACST, based on their financial statements, market capitalization, and price volatility, are BAND, NH, BDR, LIVN, and IBIO.
- ACST's SEC filings can be seen here. And to visit Acasti Pharma Inc's official web site, go to www.acastipharma.com.
ACST Valuation Summary
- In comparison to the median Healthcare stock, ACST's price/sales ratio is 9231.58% higher, now standing at 354.6.
- Over the past 116 months, ACST's EV/EBIT ratio has gone up 226.4.
- Over the past 116 months, ACST's EV/EBIT ratio has gone up 226.4.
Below are key valuation metrics over time for ACST.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ACST | 2021-08-31 | 354.6 | 1.3 | -3.8 | -1.9 |
| ACST | 2021-08-30 | 426.5 | 1.6 | -4.6 | -2.9 |
| ACST | 2021-08-27 | 442.9 | 1.6 | -4.8 | -3.1 |
| ACST | 2021-08-26 | 461.7 | 1.7 | -5.0 | -3.3 |
| ACST | 2021-08-25 | 499.5 | 1.8 | -5.4 | -3.8 |
| ACST | 2021-08-24 | 483.7 | 1.8 | -5.2 | -3.6 |
ACST's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ACST has a Quality Grade of F, ranking ahead of 1.78% of graded US stocks.
- ACST's asset turnover comes in at 0.005 -- ranking 411th of 682 Pharmaceutical Products stocks.
- FSTX, APLS, and SRRA are the stocks whose asset turnover ratios are most correlated with ACST.
The table below shows ACST's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.005 | 0.612 | -2.164 |
| 2021-03-31 | 0.006 | 0.612 | -7.694 |
| 2020-12-31 | 0.004 | 0.556 | 15.764 |
| 2020-09-30 | 0.000 | NA | 8.069 |
| 2020-06-30 | 0.000 | NA | 5.574 |
| 2020-03-31 | 0.000 | NA | 5.798 |
ACST Price Target
For more insight on analysts targets of ACST, see our ACST price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.04 | Average Broker Recommendation | 2 (Hold) |
ACST Stock Price Chart Interactive Chart >
ACST Price/Volume Stats
| Current price | $0.90 | 52-week high | $3.86 |
| Prev. close | $0.89 | 52-week low | $0.80 |
| Day low | $0.87 | Volume | 121,000 |
| Day high | $0.93 | Avg. volume | 212,301 |
| 50-day MA | $0.89 | Dividend yield | N/A |
| 200-day MA | $1.14 | Market Cap | 40.04M |
Acasti Pharma, Inc. - (ACST) Company Bio
Acasti Pharma Inc operates as pharmaceutical company. The Company develops drugs for cardiovascular diseases. Acasti offers omega-3 phospholipids a major component of cell membranes.
Latest ACST News From Around the Web
Below are the latest news stories about Acasti Pharma Inc that investors may wish to consider to help them evaluate ACST as an investment opportunity.
New Strong Sell Stocks for February 23rdARR, ACST, and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on February 23, 2022 |
Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day PodcastPhoenix, Arizona--(Newsfile Corp. - February 22, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company's background and current projects. "Acasti is a specialty Pharma company," explained D'Alvise. "We have developed a rang |
Earnings Scheduled For February 14, 2022Companies Reporting Before The Bell • Weber (NYSE: WEBR ) is projected to report quarterly loss at $0.06 per share on revenue of $310.78 million. • Kelly Services (NASDAQ: KELYB ) is expected to report earnings for its fourth quarter. • Westwater Resources (AMEX: WWR ) is likely to report earnings for its fourth quarter. • Scorpio Tankers (NYSE: STNG ) is expected to report quarterly loss at $0.75 per share on revenue of $151.10 million. • Kelly Services (NASDAQ: KELYA ) is expected to report quarterly earnings at $0.28 per share on revenue of $1.30 billion. • Garrett Motion (NASDAQ: GTX ) is projected to report quarterly earnings at $0.19 per share on revenue of $863.00 million. • Applied Genetic (NASDAQ: AGTC ) is expected to report earnings for its second quarter. • Alexander''s (NYS... |
Acasti Pharma Inc. (ACST) CEO Jan D''Alvise on Q3 2021 Results - Earnings Call TranscriptNo summary available. |
Acasti Pharma GAAP EPS of -$0.09 misses by $0.01Acasti Pharma press release (ACST): Q4 GAAP EPS of -$0.09 misses by $0.01.Cash, cash equivalents and short-term investments totaled $46.3 million as of December 31, 2021, compared… |
ACST Price Returns
| 1-mo | 3.46% |
| 3-mo | -0.01% |
| 6-mo | -21.05% |
| 1-year | -75.05% |
| 3-year | -94.23% |
| 5-year | -91.54% |
| YTD | -28.57% |
| 2021 | -51.54% |
| 2020 | -86.73% |
| 2019 | 195.18% |
| 2018 | -11.70% |
| 2017 | -24.80% |
Loading social stream, please wait...